The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUNDVersion 2 of the Collaborative Stage Data Collection System (CSv2) became effective with cases diagnosed in 2010. This report focuses on the CSv2 components required to derive the American Joint Committee on Cancer (AJCC) stage for prostate cancer and on the site‐specific factors for prostate cancer captured in CSv2. The report also highlights differences between the AJCC 6th and 7th editions...
BACKGROUNDRecent debate about prostate‐specific antigen (PSA)‐based testing for prostate cancer screening among older men has rarely considered the cost of screening.
METHODSA population‐based cohort of male Medicare beneficiaries aged 66 to 99 years, who had never been diagnosed with prostate cancer at the end of 2006 (n = 94,652), was assembled, and they were followed for 3 years to assess the...
BACKGROUNDThe current study was conducted to analyze the association between cigarette smoking and metastasis (the primary outcome) as well as time to biochemical disease recurrence (BCR), metastasis, castration‐resistant prostate cancer (CRPC), and prostate cancer‐specific and overall mortality (secondary outcomes) after radical prostatectomy among men from the Shared Equal Access Regional Cancer...
BACKGROUNDCancer screening recommendations vary widely, especially for breast, prostate, and skin cancer screening. Guidelines are provided by the American Cancer Society, the US Preventive Services Task Force, and various professional organizations. The recommendations often differ with regard to age and frequency of screening. The objective of this study was to determine actual rates of screening...
BACKGROUNDThe current study was performed to evaluate whether baseline acute and chronic prostate inflammation among men with an initial negative biopsy for prostate cancer (PCa) increased the risk of subsequent PCa detection in a clinical trial with systematic biopsies.
METHODSA retrospective analysis was performed of 6238 men aged 50 years to 75 years with prostate‐specific antigen levels between...
BACKGROUNDProstate cancer treatment after failure of primary therapy by either radical prostatectomy or radiation therapy can vary greatly. This study sought to determine trends and predictors of salvage treatment after failure of primary treatment in a community cohort over the past 10 years.
METHODSFrom the community‐based Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database,...
BACKGROUNDProstate cancer mortality in the United States has declined by nearly 40% over the last 25 years. However, to the authors' knowledge, the contribution of prostate‐specific antigen (PSA) screening for the early detection of prostate cancer remains unclear and controversial. In the current study, the authors attempted to determine whether improvements in survival over time among patients with...
BACKGROUNDIn 1999 and 2000, 2 national guidelines recommended brachytherapy monotherapy (BT) primarily for treatment of low‐risk prostate cancer but not high‐risk prostate cancer. This study examined rates of BT use before and after publication of these guidelines, as compared with 4 other treatment options.
METHODSFrom 1990 to 2011, 8128 men with localized prostate cancer (≤ T3cN0M0) were treated...
BACKGROUNDData continue to emerge on the relative merits of different treatment modalities for prostate cancer. The objective of this study was to compare patient‐reported quality‐of‐life (QOL) outcomes after proton therapy (PT) and intensity‐modulated radiation therapy (IMRT) for prostate cancer.
METHODSA comparison was performed of prospectively collected QOL data using the Expanded Prostate Cancer...
BACKGROUNDEnzalutamide (Enz) and abiraterone acetate (AA) are hormone treatments that have a proven survival advantage in patients with metastatic, castration‐resistant prostate cancer who previously received docetaxel (Doc). Recently, limited activity of AA after Enz and of Enz after AA was demonstrated in small cohort studies. Here, the authors present the activity and tolerability of Enz in patients...
BACKGROUNDThe authors investigated the prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction in a contemporary, population‐based prostate cancer cohort. They also explored the associations between baseline function and age, comorbidity, and timing of baseline survey completion with respect to treatment.
METHODSThe Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR)...
Androgen deprivation therapy (ADT) is now a well‐established standard of care in combination with definitive radiotherapy for patients with unfavorable intermediate‐risk to high‐risk locally advanced prostate cancer. It is also well established that combination modality treatment with ADT and radiotherapy is superior to either of these modalities alone for the treatment of patients with high‐risk...
BACKGROUNDRecently, men with intermediate‐risk prostate cancer (PC) were classified into favorable and unfavorable categories; however, whether the risk of PC‐specific mortality (PCSM) among men with high‐risk PC versus unfavorable intermediate‐risk PC is increased is unknown.
METHODSIn a prospective, randomized trial conducted between 1995 and 2001, 206 men with intermediate‐risk or high‐risk PC...
BACKGROUNDThe clinical course of prostate cancer (PCa) measured by biochemical failure (BF) after prostatectomy remains unpredictable in many patients, particularly in intermediate Gleason score (GS) 7 tumors, suggesting that identification of molecular mechanisms associated with aggressive PCa biology may be exploited for improved prognostication or therapy. Hyaluronan (HA) is a high molecular weight...
There remains no standard of care for patients with a rising prostate‐specific antigen level after radical prostatectomy or radiotherapy but who have no radiographic metastases, even though this is the second largest group of patients with prostate cancer (CaP) in the United States. Androgen deprivation therapy (ADT) may cure some men with advanced CaP based on single‐institution series and a randomized...
BACKGROUNDDecisional conflict is a source of anxiety and stress for men diagnosed with prostate cancer given uncertainty surrounding myriad treatment options. Few data exist to help clinicians identify which patients are at risk for decisional conflict. The purpose of this study was to examine factors associated with decisional conflict in economically disadvantaged men diagnosed with prostate cancer...
BACKGROUNDThe survival of men diagnosed with prostate cancer has improved over time, and the current 10‐year relative survival rate is 99.7%. The long survival of patients with this common cancer raises questions about the risk of a second primary cancer and the need for continued surveillance.
METHODSA population‐based cohort of 441,504 men who were diagnosed with prostate cancer between 1992 and...
BACKGROUNDUS Food and Drug Administration (FDA) approval of new drugs depends on results from clinical trials that must be generalized to the US population. However, racial minorities are frequently under‐represented in clinical studies. The enrollment of racial minorities was compared in key clinical studies submitted to the FDA in the last 10 years in support of potential marketing approval for...
BACKGROUNDThe 2013 American Urological Association/American Society for Radiation Oncology consensus guidelines recommend offering adjuvant radiotherapy (RT) after radical prostatectomy in patients with high‐risk pathologic features for recurrence. In the current study, the authors examined practice patterns of adjuvant RT use in patients with elevated pathologic risk factors over a time period spanning...
BACKGROUNDNuclear factor κB (NFκB) signaling is strongly associated with tumor progression, and studies have shown that SHANK‐associated RH domain interacting protein (SHARPIN) is crucial for NFκB pathway activation. However, the expression and functions of SHARPIN in prostate cancer (PCa) have not yet been defined.
METHODSThe expression of SHARPIN in PCa cell lines and tissues was evaluated with...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.